Head and Neck Cancer Immunotherapy beyond the Checkpoint Blockade

Area of Science:

• Oncology
• Immunology
• Cancer Genomics

Background:

• Immune checkpoint blockade shows promise for head and neck squamous cell carcinoma (HNSCC) treatment.
• However, fewer than 15% of HNSCC patients respond, highlighting significant resistance.
• Genomic alterations in HNSCC can suppress immune sensing, impacting both innate and adaptive immunity.

Purpose of the Study:

• To review recent advances in identifying HNSCC oncogenes that impair anti-tumor immunity.
• To discuss emerging immune-priming strategies to sensitize HNSCC to checkpoint blockade.
• To explore novel therapeutic approaches for improving immunotherapy response rates in HNSCC.

Main Methods:

• Literature review of recent advances in HNSCC immunotherapy resistance.
• Analysis of oncogenic mechanisms suppressing immune sensing in HNSCC.
• Exploration of immune-priming strategies including cancer vaccines, radiation, DNA damage agents, and metabolic reprogramming.

Main Results:

• Key HNSCC oncogenes have been identified that inhibit innate and adaptive anti-tumor immune responses.
• Immune-priming strategies aim to enhance T-cell expansion, overcome immune tolerance, and support T-cell activation.
• Novel approaches like type I interferon agonists, radiation, and metabolic reprogramming show potential for sensitizing HNSCC to immunotherapy.

Conclusions:

• Targeting oncogenic inhibition of immune sensing is a promising strategy to improve HNSCC immunotherapy.
• Multifaceted approaches are needed to expand the pool of responders to checkpoint blockade in HNSCC.
• Further research into HNSCC immune regulators, improved mouse models, and adjuvant delivery systems is essential for clinical translation.